Premium
In Vivo Evaluation of a MPC Polymer Coated Continuous Flow Left Ventricular Assist System
Author(s) -
Kihara Shin’ichiro,
Yamazaki Kenji,
Litwak Kenneth N.,
Litwak Philip,
Kameneva Marina V.,
Ushiyama Hiroyuki,
Tokuno Toshimasa,
Borzelleca David C.,
Umezu Mitsuo,
Tomioka Jun,
Tagusari Osamu,
Akimoto Takehide,
Koyanagi Hitoshi,
Kurosawa Hiromi,
Kormos Robert L.,
Griffith Bartley P.
Publication year - 2003
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1046/j.1525-1594.2003.t01-2-06993.x
Subject(s) - thrombogenicity , biocompatibility , materials science , coating , biomedical engineering , surface modification , polymer , thrombus , medicine , cardiology , nanotechnology , surgery , composite material , metallurgy , chemical engineering , thrombosis , engineering
The aim of this study was the evaluation of the thrombogenicity and the biocompatibility of the SunMedical EVAHEART left ventricular assist system (LVAS) coated with 2‐methacryloyloxyethyl phosphorylcholine (MPC) polymer compared to a diamond‐like carbon (DLC) coating. Four calves were implanted with the MPC polymer‐coated LVAS. Eight calves were implanted with DLC coated LVAS. The thrombogenicity and biocompatibility of the pumps were evaluated. At explant, 60.0 ± 37.2% (5‐85%) of the pump surface area was still coated with MPC polymer after the duration of 45.0 ± 32.0 days. In 1 out of 4 MPC and 2 out of 8 DLC coated pumps, there was a very small amount of thrombus around the seal ring; otherwise the blood contacting surfaces were free of thrombus. Major organs were normal except for a few lesions in kidneys from both groups. The MPC polymer coated EVAHEART LVAS seems to have low thrombogenicity and high biocompatibility similar to the DLC coated system. The current study demonstrated that the MPC polymer coating shows great promise for being used as an antithrombogenic substrate for the LVAS due to its ease of application, significant cost benefit, and reduction in anticoagulation therapy in acute postoperative period.